ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Improving Pharma R&D Efficiency
This article explores the need for a holistic and integrated approach to improve clinical trial efficiencies.
Hybrid Study Designs & the Link Between RWE, Epidemiology
Read how hybrid study designs can be advantageous for the generation of RWE, providing a potential solution to the challenges presented by observational studies.
Integrated Technology Platform For Adaptive Clinical Trials
The new platform, ADDPLAN® neo combines modules from pre- existing technology for adaptive clinical trials
FDA Guidance on Communicating with Payers
Read more about significant provisions in recent FDA guidance documents and the key takeaways for manufacturers when sharing health economic data with payers
Digital Trials A Framework for Success
There is increasing interest in digital trials, that is the use of mHealth and mobile technology to capture insights outside the traditional clinical research setting
Challenges Associated with new EU MDR and IVDR
Vicki Anastasi, and Karen Hill, ICON, examine the key challenges associated with new EU MDR and IVDR.
Ready or Not, Medtech Braces For New EU Landscape
The EU's new Medical Device Regulation is set to take effect in May 2020 and the In Vitro Diagnostics Regulation two years later.
Using Economic Models to Gain Early Access
Early access schemes demand new ways of performing health economic evaluations. This means developing health economic models
What ICER Pricing Would Mean for U.S. Drug Spend
ICER has become a major force in payer–manufacturer price negotiations.
CROs Must Be Aware Of Threat Posed By Big Tech
ICON’s CEO Steve Cutler discusses the impact of biotech funding, disruptive tech providers, and the constant pressure of running one of the industry’s largest CROs.